Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $6.25
Portfolio Pulse from Benzinga Newsdesk
Ascendiant Capital analyst Edward Woo maintains a Buy rating on Atossa Therapeutics (NASDAQ:ATOS) and raises the price target from $6 to $6.25.
June 06, 2024 | 5:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ascendiant Capital analyst Edward Woo maintains a Buy rating on Atossa Therapeutics and raises the price target from $6 to $6.25.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100